{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:10:50Z","timestamp":1785352250845,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jval.2022.12.011","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:29:53Z","timestamp":1671748193000},"page":"810-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus"],"prefix":"10.1016","volume":"26","author":[{"given":"Iro","family":"Chatzidaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Luedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan J.","family":"Mezzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"Eddowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2022.12.011_bib1","first-page":"5","article-title":"HIV virology and pathogenetic mechanisms of infection: a brief overview","volume":"46","author":"Fanales-Belasio","year":"2010","journal-title":"Ann Ist Super Sanita"},{"issue":"18","key":"10.1016\/j.jval.2022.12.011_bib3","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2174\/1568026619666190712204603","article-title":"Discovery and development of anti-HIV therapeutic agents: progress towards improved HIV medication","volume":"19","author":"Maeda","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jval.2022.12.011_bib4","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3389\/fmicb.2017.02323","article-title":"Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy","volume":"8","author":"Iacob","year":"2017","journal-title":"Front Microbiol"},{"issue":"14","key":"10.1016\/j.jval.2022.12.011_bib6","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"issue":"suppl 8","key":"10.1016\/j.jval.2022.12.011_bib7","first-page":"55","article-title":"Outcomes of patients not achieving primary endpoint from an ibalizumab phase III trial [Conference abstract]","volume":"21","author":"DeJesus","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"9581","key":"10.1016\/j.jval.2022.12.011_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jval.2022.12.011_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAI.0b013e3181a4f00d","article-title":"Quality of life of patients with advanced HIV\/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events","volume":"51","author":"Anis","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"13","key":"10.1016\/j.jval.2022.12.011_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2022.12.011_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1468-1293.2011.00953.x","article-title":"Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematic review and meta-analysis of recent randomized controlled trials","volume":"13","author":"Pichenot","year":"2012","journal-title":"HIV Med"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.12.011_bib12","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.jval.2020.04.514","article-title":"Pin43 health care resource utilization and cost of heavily treatment experienced (HTE) people living with HIV (PLWH) in US commercial and Medicare advantage health plans [Conference abstract]","volume":"23","author":"Priest","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2022.12.011_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3851\/IMP1519","article-title":"Treatment simplification to once daily darunavir\/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients","volume":"15","author":"Molto","year":"2010","journal-title":"Antivir Ther"},{"issue":"8","key":"10.1016\/j.jval.2022.12.011_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/605674","article-title":"Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial","volume":"49","author":"De Castro","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2022.12.011_bib15","article-title":"The management of treatment-experienced HIV patients (including virologic failure and switches)","volume":"7","author":"Cutrell","year":"2020","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"10.1016\/j.jval.2022.12.011_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9459(24)07757-X","article-title":"The pharmacology of HIV drug resistance","volume":"70","author":"Zdanowicz","year":"2006","journal-title":"Am J Pharm Educ"},{"issue":"16","key":"10.1016\/j.jval.2022.12.011_bib19","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society\u2013USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2022.12.011_bib20","author":"Grulich"},{"issue":"6","key":"10.1016\/j.jval.2022.12.011_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jval.2022.12.011_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"issue":"7822","key":"10.1016\/j.jval.2022.12.011_bib31","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jval.2022.12.011_bib32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A\u00a0highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.jval.2022.12.011_bib34","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2022.12.011_bib35","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-9-1","article-title":"HIV: how to manage heavily treatment-experienced patients","volume":"11","author":"Spivack","year":"2022","journal-title":"Drugs Context"},{"key":"10.1016\/j.jval.2022.12.011_bib38","author":"Higgins"},{"key":"10.1016\/j.jval.2022.12.011_bib39","series-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","year":"2008"},{"key":"10.1016\/j.jval.2022.12.011_bib40","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2022.12.011_bib41","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: a tool for assessing risk\u00a0of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.12.011_bib42","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1093\/ofid\/ofaa439.1213","article-title":"Long-term efficacy, safety, and durability of ibalizumab-based regimens in subgroup of TMB-202 participants","volume":"7","author":"Towner","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"9581","key":"10.1016\/j.jval.2022.12.011_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jval.2022.12.011_bib44","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/QAD.0b013e32832cdc26","article-title":"Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients","volume":"23","author":"Viard","year":"2009","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.jval.2022.12.011_bib45","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/jmv.23388","article-title":"Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study","volume":"84","author":"Morand-Joubert","year":"2012","journal-title":"J\u00a0Med Virol"},{"issue":"3","key":"10.1016\/j.jval.2022.12.011_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/135965350801300304","article-title":"A\u00a0randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study)","volume":"13","author":"Boyd","year":"2008","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.jval.2022.12.011_bib49","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial","volume":"201","author":"Suleiman","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"12","key":"10.1016\/j.jval.2022.12.011_bib50","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1128\/AAC.00467-08","article-title":"Safety and efficacy of enfuvirtide in combination with Darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study","volume":"52","author":"DeJesus","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jval.2022.12.011_bib51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3851\/IMP1833","article-title":"Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART","volume":"16","author":"Nicastri","year":"2011","journal-title":"Antivir Ther"},{"issue":"9893","key":"10.1016\/j.jval.2022.12.011_bib52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"issue":"suppl\u00a04","key":"10.1016\/j.jval.2022.12.011_bib53","first-page":"O51","article-title":"Activity of the integrase inhibitor S\/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)","volume":"13","author":"Eron","year":"2010","journal-title":"J\u00a0Int AIDS Soc"},{"issue":"3","key":"10.1016\/j.jval.2022.12.011_bib54","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir-and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"Castagna","year":"2014","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.jval.2022.12.011_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir Ther"},{"issue":"10","key":"10.1016\/j.jval.2022.12.011_bib56","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14656566.2018.1484901","article-title":"Darunavir for the treatment of HIV infection","volume":"19","author":"Spagnuolo","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.jval.2022.12.011_bib58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2022.12.011_bib59","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A\u00a0simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"30","key":"10.1016\/j.jval.2022.12.011_bib60","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: a simulation study","volume":"39","author":"Phillippo","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2022.12.011_bib61","author":"Phillippo"},{"issue":"9","key":"10.1016\/j.jval.2022.12.011_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jval.2022.12.011_bib63","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jval.2022.12.011_bib64","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","article-title":"Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: an update on a systematic review and network meta-analysis","volume":"21","author":"Nickel","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"10","key":"10.1016\/j.jval.2022.12.011_bib65","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.jval.2022.12.011_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/15284336.2016.1261073","article-title":"Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic review and meta-analysis","volume":"18","author":"Ewald","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jval.2022.12.011_bib67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3389\/fphar.2018.00890","article-title":"Assessing the efficacy of lopinavir\/ritonavir-based preferred and alternative second-line regimens in HIV-infected patients: a meta-analysis of key evidence to support WHO recommendations","volume":"9","author":"Huang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2022.12.011_bib68","author":"Welton"},{"key":"10.1016\/j.jval.2022.12.011_bib69","article-title":"Lenacapavir (LEN) Marketing Authorization Application (MAA)","year":"2021","journal-title":"Rapporteur\/Co-rapporteur\/EMA meeting"},{"key":"10.1016\/j.jval.2022.12.011_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.jval.2022.12.011_bib71","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/hiv.12567","article-title":"Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion","volume":"19","author":"Stirrup","year":"2018","journal-title":"HIV Med"},{"issue":"2","key":"10.1016\/j.jval.2022.12.011_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084276","article-title":"Factors related to changes in CD4+ T-cell counts over time in patients living with HIV\/AIDS: a multilevel analysis","volume":"9","author":"Montarroyos","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2022.12.011_bib73","series-title":"Potent antiviral activity of lenacapavir in phase 2\/3 in heavily art-experienced PWH. CROI","author":"Segal-Maurer","year":"2021"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:16Z","timestamp":1761096736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1098301522047854"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}